Immune response to an indigenously developed hepatitis-B ( Shanvac-B) vaccine in a tribal community of India

Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed ( Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and an...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Vaccine Ročník 20; číslo 29; s. 3431 - 3435
Hlavní autoři: Murhekar, M.V, Murhekar, K.M, Arankalle, V.A, Sehgal, S.C
Médium: Journal Article
Jazyk:angličtina
Vydáno: Oxford Elsevier Ltd 04.10.2002
Elsevier
Témata:
Adolescent
Adult
Andaman and Nicobar Islands
Biological and medical sciences
Child
Child, Preschool
Epidemiology. Vaccinations
Female
Fundamental and applied biological sciences. Psychology
General aspects
Hepatitis B Antibodies - blood
Hepatitis B Vaccines - adverse effects
Hepatitis B Vaccines - immunology
Hepatitis-B
Hepatitis-B vaccine
Humans
India
Infant
Infant, Newborn
Infectious diseases
Male
Medical sciences
Microbiology
Tribes
Vaccination
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies
Virology
Asia
India
Hepatitis-B
Hepatitis-B vaccine
Tribes
Andaman and Nicobar Islands
India
Human
Sanitary program
Treatment efficiency
Vaccination
Orthohepadnavirus
Hepatic disease
Vaccine
Cost benefit ratio
Infection
Virus
Viral hepatitis B
Hepadnaviridae
Viral disease
Digestive diseases
Community health
Safety
Hepatitis B virus
ISSN:0264-410X, 1873-2518
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Hepatitis-B infection is highly endemic among the primitive tribes of Andaman and Nicobar Islands, India. A pilot project of hepatitis-B vaccination using indigenously developed ( Shanvac-B) was initiated among the Nicobarese tribe in Car Nicobar Island. The 936 individuals negative for HBsAg and anti-HBs were administered three doses of the vaccine at 0, 1 and 6 months. The vaccine was found to be safe and efficacious with sero-protection rates of 49.1, 86.9 and 96.7% after first, second and third dose. Considering the high endemicity of the infection and small number of the tribal population, it is necessary to initiate hepatitis-B vaccination programme for this community. Since the vaccine was found to be cost-effective, it could be adopted for hepatitis-B vaccination in this community.
Bibliografie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(02)00337-7